7 completed. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Immunogenicity: new trials by email Literature Review of Immunogenicity trials Research Report on Immunogenicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, Placebo - COVID-19 Pandemic, Immunogenicity | Phase 2 | Completed | Sheba Medical Center | 179 | 2022-09-05 | 2024-02-21 |
| Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222 - Covid-19, Vaccine | Phase 2 | Completed | Chang Gung Memorial Hospital | 100 | 2021-09-15 | 2026-06-15 |
| Protectivity and Safety Following Recombinant Hepatitis B Vaccine Recombinant Hepatitis B vaccine, Recombinant Hepatitis B (Bio Farma) - Immunogenicity | Phase 2 / Phase 3 | Completed | PT Bio Farma | 536 | 2019-09-11 | 2022-09-19 |
| EMaBS TB Vaccine Study ChAdOx185A, MVA85A, BCG - Safety, Immunogenicity | Phase 1 / Phase 2 | Completed | University of Oxford | 72 | 2019-07-01 | 2022-08-05 |
| Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants Vi-DT Vaccine, Vi Polysaccharide Vaccine, IPV Vaccine - Safety Issues, Immunogenicity | Phase 2 | Completed | PT Bio Farma | 600 | 2018-07-16 | 2020-02-20 |
| A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique HIVIS DNA vaccine, Zetajet, Derma Vax Electroporation - Vaccines, HIV | Phase 2 | Completed | Muhimbili University of Health and Allied Sciences | 198 | 2012-11-01 | 2015-06-29 |
| A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants 160U /0.5ml EV71 Vaccine, 320U /0.5ml EV71 vaccine, 640U /0.5ml EV71 vaccine - Immunogenicity, Safety | Phase 2 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 1200 | 2011-07-01 | 2012-05-31 |
COVID-19 (2) · Tuberculosis (1)
Infections (3) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Lung Diseases (2) · Nidovirales Infections (2) · Pneumonia (2) · Pneumonia, Viral (2) · RNA Virus Infections (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Virus Diseases (2) · Actinomycetales Infections (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Gram-Positive Bacterial Infections (1)
2019-nCoV Vaccine mRNA-1273 (1) · Adjuvants, Pharmaceutic (1) · ChAdOx1 nCoV-19 (1) · Hepatitis B Vaccines (1) · MVA 85A (1) · MVC-COV1901 vaccine (1) · Vi polysaccharide vaccine, typhoid (1) · mRNA-1273.214 COVID-19 vaccine (1) · smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (1)
PT Bio Farma (2) · Chang Gung Memorial Hospital (1) · Jiangsu Province Centers for Disease Control and Prevention (1) · Muhimbili University of Health and Allied Sciences (1) · Sheba Medical Center (1) · University of Oxford (1)
Indonesia (2) · China (1) · Israel (1) · Mozambique (1) · Taiwan (1) · Tanzania (1) · Uganda (1) · United Kingdom (1)
Bernie Endyarni, MD (1) · Gili Regev-Yochay, MD (1) · Helen McShane, Professor (1) · Yetty M Nency, MD (1)
PMID 23352749, PMID 30121146, PMID 32004693, PMID 33059607, PMID 36115850, PMID 38297337, PMID 38806352, PMID 42648772